Intravitreal injection is fast, familiar, and highly effective, which is why it remains the default for retinal delivery. But its safety, immune, and physiological limits cap how far conventional IVT can really go.
As retinal therapies grow larger and more complex, it’s time to look beyond IVT while there’s still room to manoeuvre. David Cottenden from TTP’s Drug Delivery team unpacks this in the video below.
About TTP's Drug Delivery team
TTP’s Drug Delivery experts specialise in designing and engineering advanced drug delivery systems and combination devices, solving complex formulation and delivery challenges, and engineering robust, scalable devices for diverse therapies and routes of administration.
Backed by a broader team of 350+ scientiss, engineers and human factors specialists, TTP enables reliable real-world performance and has contributed to more than 70 systems, spanning autoinjectors and inhalation devices through to microneedles, infusion pumps and advanced local-delivery platforms. Find out more.
